news_6

Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

- QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status - -...

news_6

Malaysia Telecom Operators Country Intelligence Report 2020 – Digi, Maxis, and Celcom Accounted for 69.8% of the Total Mobile Subscriptions in 2019 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Malaysia Telecom Operators Country Intelligence 2020" report has been added to ResearchAndMarkets.com's offering. Malaysia Telecom Operators Country Intelligence...

news_6

Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together...

news_6

FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases Inflazome announced positive...